Abstract
From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 1335-1341 |
| Number of pages | 7 |
| Journal | Journal of Clinical Oncology |
| Volume | 8 |
| Issue number | 8 |
| Publication status | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Intraperitoneal carboplatin : Favorable results in women with minimal residual ovarian cancer after cisplatin therapy. / Speyer, J. L.; Beller, U.; Colombo, N.; Sorich, J.; Wernz, J. C.; Hochster, H.; Green, M.; Porges, R.; Muggia, F. M.; Canetta, R.; Beckman, E. M.
In: Journal of Clinical Oncology, Vol. 8, No. 8, 1990, p. 1335-1341.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intraperitoneal carboplatin
T2 - Favorable results in women with minimal residual ovarian cancer after cisplatin therapy
AU - Speyer, J. L.
AU - Beller, U.
AU - Colombo, N.
AU - Sorich, J.
AU - Wernz, J. C.
AU - Hochster, H.
AU - Green, M.
AU - Porges, R.
AU - Muggia, F. M.
AU - Canetta, R.
AU - Beckman, E. M.
PY - 1990
Y1 - 1990
N2 - From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.
AB - From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m 2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m 2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.
UR - http://www.scopus.com/inward/record.url?scp=0024989883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024989883&partnerID=8YFLogxK
M3 - Article
VL - 8
SP - 1335
EP - 1341
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
SN - 0732-183X
IS - 8
ER -